Research programme: anti-infectives - TransaveAlternative Names: Anti-infectives research programme - Transave; SLIT™ TR04; TR 04
Latest Information Update: 19 Mar 2011
At a glance
- Originator Transave
- Developer Insmed
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Anthrax
Most Recent Events
- 02 Dec 2010 Transave has been acquired and merged into Insmed
- 22 Jun 2005 This programme is still in active development - (BIO-2005)
- 13 Jul 2004 Preclinical trials in Anthrax in USA (Inhalation)